ArticleDiscover oncology2025
Fedratinib inhibits ovarian cancer progression by downregulating QPCT expression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAmong gynecological malignant tumors, ovarian cancer is one of the most common, and the death rate is the highest. However, most ovarian cancer patients will be resistant to the application of Olaparib. Searching for novel therapeutic agents and targets for ovarian cancer is crucial.
methodsIn order to study the effect of Fedratinib on ovarian cancer cells, we used CCK-8, scratch assay, Transwell assay, cell cycle assay and Immunohistochemical detection. To explore the regulatory impact of Fedratinib on QPCT gene, we have included Western blotting, Rescue experiment, and other methods.
resultsIn this study, we screened Fedratinib, a Janus kinase 2 inhibitor, a drug candidate for ovarian cancer using bioinformatics combined with cellular assays. Fedratinib had a significant impact on the proliferation of ovarian cancer cells, and the potential target of Fedratinib might be QPCT. The expression of QPCT was significantly elevated in ovarian cancer tissue samples and ovarian cancer cells, and cell proliferation, migration, and invasion were enhanced by the overexpression of QPCT. However, the expression of QPCT was significantly downregulated in the cells after treatment with Fedratinib, and cell viability induced by knockdown of QPCT decline can be reversed by Ferroptosis inhibitors and Necroptosis inhibitors.
conclusionsFedratinib suppresses QPCT expression, which might associated with inhibition of JAK-STAT signaling, thus inhibiting the growth of ovarian cancer cells through Ferroptosis or Necroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.